Loading
A phase 2 trial of PM8002, Paclitaxel / nab-paclitaxel, Gemcitabine in pancreatic ductal adenocarcinoma, run by BioNTech SE, now recruiting.
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer is a phase 2 interventional study registered as NCT07255404 by BioNTech SE, with 105 participants planned, started 2025-12-04 and due to reach its primary completion in 2027-12. Interventions recorded: Pumitamig, Nab-paclitaxel, Gemcitabine, mFOLFIRINOX. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, BioNTech, Gemcitabine.
Shares PM8002, BioNTech, Paclitaxel / nab-paclitaxel.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/